Nephropathy is a hot research topic, especially in relation to its link with Diabetes (already 6 500 publications so far referenced in pubmed to date for 2019, a third of them in relation to type I or type II diabetes). As nephropathy can lead to life endangering end-stage renal diseases (ESRDs) with a severe impact on life expectancy, a lot of research is being undertaken to find new drugs to beat this potentially severe condition. Several biomarkers of this pathology have already been identified such as CD27 antigen, kidney injury molecule 1 (KIM-1) and α1-microglobulin in relation to type I diabetes (1), in addition to the well known Clusterin, Cystatin-C, Microalbumin and Beta-2 Microglobulin.

Thanks to its capability to recruit the natural protein degradation system of a cell, PROTACs (PROteolysis TArgeting Chimera) appears as a very promising technology in cancer therapy and disease treatment. As a distributor of innovative reagents for life science researchers, tebu-bio provides you with all the necessary tools to develop or test your own PROTACs system.

Are you looking for a simple means to boost the efficiency of gene editing and also to reduce the off-target? Yes, it does exist – in one word: 4-hydroxy Tamoxifen. That’s the HIT-CAS9.

Hybrid drug inducible CRISPR/Cas9 technology, HIT-Cas9

Zhao et al revealed tight and effective drug control of the CRISPR Cas9 based on 4-Hydroxytamoxifen. doi: 10.1016/j.omtn.2018.08.022

They built a fusion between a mutated human estrogen receptor (ERT2) and the Cas9 endonucelase, which makes the CRISPR Cas9 dependent on 4-hydroxytamoxifen.

When it comes to proteomics and broad protein profiling (and/or quantification), two main technologies come to mind: Mass Spectrometry and Antibody Arrays. Rather than opposing each other, they appear more as complementary in the chase for Biomarker discovery.

Indeed, each technique has its own advantages and limitations. Combining the two can contribute to more accurate identification of relevant biomarkers. Going one step further, biomarker identification performed by Mass Spec can be confirmed by Antibody Arrays.